Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06143631
Other study ID # 23-39255
Secondary ID R01HD112465
Status Recruiting
Phase Phase 4
First received
Last updated
Start date June 14, 2024
Est. completion date April 30, 2027

Study information

Verified date June 2024
Source University of California, San Francisco
Contact Vanessa Jacoby, MD, MAS
Phone 415-514-8299
Email vanessa.jacoby@ucsf.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The PLUM Study is a randomized, double-blinded, 2-arm, parallel-group, placebo-controlled trial is designed to compare the efficacy of letrozole versus placebo on leiomyoma-related symptoms and quality of life as well as leiomyoma and uterine size.


Recruitment information / eligibility

Status Recruiting
Enrollment 140
Est. completion date April 30, 2027
Est. primary completion date January 30, 2027
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 21 Years to 53 Years
Eligibility Inclusion Criteria: - At least 21 and less than 54 years of age (to focus on an adult, premenopausal population) - Female sex, based on sex identified on their birth certificate (no other gender requirements) - Have uterine leiomyomata that have been visualized on pelvic imaging (i.e., ultrasound or MRI) in the last 24 months - Report symptoms associated with leiomyomata such as heavy uterine bleeding, pelvic pressure or discomfort, urinary or bowel abnormalities, or dyspareunia for the past 3 months - Have at least moderate leiomyomata symptom burden, with UFS-QOL SSS score of 30 or higher at baseline - Has regularly-occurring menstrual periods of = 14 days duration with a cycle of 21 to 38 days from the start of one menstrual period until the start of the next, by patient history for at least 3 months prior to screening - Agree to use a non-hormonal barrier method of contraception during the study period if at risk for pregnancy (any sexual activity with a non-sterile male partner) Exclusion Criteria: - Screening pelvic imaging indicating any leiomyomata =8 cm in maximum diameter, or uterine size =14 cm in length (equivalent to 14 weeks gestation)-note that candidates who exclusively have prior clinical pelvic imaging 12-24 months ago will be excluded if imaging includes leiomyomata =7 cm in maximum diameter, or uterine size =13 cm in length, presuming leiomyoma growth of =1 cm per year - Screening pelvic imaging indicating only one, sole leiomyoma <2 cm in maximum diameter - Any submucosal leiomyoma that is <50% within uterine cavity (FIGO Type 0 or Type 1 leiomyomata) - Visit to the emergency room or hospitalization for leiomyoma symptoms in the last 12 weeks - Leiomyomata treated by surgery, radiologic procedure in the last 12 weeks; or plans to undergo any of the above in the next 24 weeks - Leiomyomata treated by GRNH agonist or antagonist in the last 12 weeks; or plans to use the above in the next 24 weeks - Currently pregnant or lactating, pregnant or lactating in the past 12 weeks, or planning to become pregnant in the next 24 weeks - Screening serum hemoglobin <8 g/dL, or history of blood transfusion in the last 12 weeks (indicating severe anemia) - Screening cholesterol lipid panel testing showing LDL cholesterol level = 190 mg/dL (due to rare side effects over long-term use of aromatase inhibitors in postmenopausal women) - Screening serum estradiol level <30 pg/mL (consistent with postmenopausal status) - Age =45 years with irregularly timed, heavy bleeding that has not yet been evaluated by endometrial biopsy, or endometrial biopsy indicating hyperplasia or malignancy - History of osteoporosis (based on self-reported DEXA indicating bone mineral density Z-score < -2.0 at spine, total hip, or femoral neck; a prior fracture judged to be a fragility fracture; or self-reported use of bisphosphonates, calcitonin, calcitriol, ipriflavone, teriparatide, or denosumab for bone density loss) - History of severe liver disease (Child Pugh Class C cirrhosis), posing safety risks for use of letrozole - Current or prior history of breast cancer (given potential need to take letrozole for breast cancer treatment or secondary prevention) - Screening pelvic imaging indicating an Ovarian-Adnexal Reporting and Data System (O-RADS) category 3, 4, or 5 ovarian or adnexal lesion - Screening pelvic imaging concerning for other current cancer of the gynecologic, genitourinary or gastrointestinal system - Prior hypersensitivity or significant adverse reaction to letrozole or any aromatase inhibitor, or to an ingredient in the placebo capsule - Use of letrozole, other aromatase inhibitor, or selective estrogen receptor modulator (SERM) medications in the past 4 weeks, or existing plans to initiate one of these in the next 24 weeks - Use of oral, vaginal, or topical exogenous estrogen, progestin, or androgen therapy in the past 4 weeks; or injectable forms of the above in the past 12 weeks; or plans to initiate any of the above in the next 24 weeks - Use of medications with potential unsafe interactions with letrozole in the past 4 weeks (methadone, levomethadone, nintedanib, thalidomide), or plans to initiate these in the next 24 weeks - Any condition that, in the opinion of the investigators, would interfere with ability to complete study procedures, including acute or uncontrolled mental health condition, substance abuse, or inability to complete procedures in English (or Spanish, for sites that offer study assessments in Spanish)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Letrozole 2.5mg
Oral letrozole 2.5mg/day
Other:
Placebo
Placebo capsule

Locations

Country Name City State
United States University of Mississippi Medical Center Jackson Mississippi
United States University of California, Sans Francisco San Francisco California

Sponsors (2)

Lead Sponsor Collaborator
University of California, San Francisco Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Uterine leiomyoma-related symptom severity over 12 weeks of treatment Change in Uterine Fibroid Symptoms Quality of Life (UFS-QOL) Symptom Severity Scale (SSS) score [Range 8-40 with higher score indicating worse symptoms and worse outcomes] Baseline to 12 weeks
Secondary Uterine leiomyoma-related quality of life over 12 weeks of treatment Change in Uterine Fibroid Symptoms Quality of Life (UFS-QOL) Health-Related QOL component score [Range 29-145 points, with higher score indicating better QoL and better outcomes] Baseline to 12 weeks
Secondary Total leiomyoma volume over 12 weeks of treatment Change in total leiomyoma volume based on pelvic ultrasound measurements Baseline to 12 weeks
Secondary Total uterine volume over 12 weeks of treatment Change in total uterine volume based on pelvic ultrasound measurements Baseline to 12 weeks
Secondary Symptoms of heavy menstrual bleeding Change in symptoms of heavy menstrual bleeding based on a modified Menstrual Bleeding Questionnaire (MBQ) score [Range 0-48 with higher MBQ score indicating worse symptoms and a negative impact on quality of life] Baseline to 12 weeks
Secondary Improvement in Sexual Functioning Change in pelvic problems-related sexual function as measured by the Sexual Health Outcomes in Women Questionnaire (SHOW-Q) Pelvic Problems Interference subscale score [Range 0-100 with higher scores indicating better sexual function] Baseline to 12 weeks
Secondary Symptoms of pelvic pain Change in pelvic pain severity/intensity "on average" (evaluated on a standard numerical rating scale of 0-10, lower rating indicating better outcomes and less pain) Baseline to 12 weeks
Secondary Symptoms of urogenital distress Change in distressing urogenital symptoms such as urinary frequency, urinary incontinence, and genital pain, as measured by Urogenital Distress Inventory-6 (UDI-6) [Range 0-100 with higher scores indicating higher disability/worse outcomes] Baseline to 12 weeks
Secondary Effect of letrozole on serum cholesterol levels Change in serum LDL cholesterol levels Baseline to 12 weeks
Secondary Effect of letrozole on serum estradiol levels Change in serum estradiol levels Baseline to 12 weeks
Secondary Effect of letrozole on frequency of hot flashes Change in frequency of vasomotor symptoms (hot flashes) as measured by the Hot Flush Rating Scale (HFRS) [no scale range but less # of reported hot flashes indicates better outcome] Baseline to 12 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04172272 - The Influence of TAP Block in the Control of Postoperative Pain After Laparotomy for Gynecological Procedures N/A
Terminated NCT02940041 - Concordance Between Sonography Amd MRI for Presurgical Diagnosis of Uterine Mesenchymal Malignant Tumors
Withdrawn NCT00768742 - Safety and Effectiveness Study of RF Ablation of Uterine Fibroids to Reduce Menstrual Bleeding: the Fibroid Ablation Study N/A
Completed NCT00156195 - Study to Evaluate the Safety of Asoprisnil in the Treatment of Uterine Fibroids Phase 3
Completed NCT00152256 - A Study to Evaluate of the Safety and Effectiveness of Asoprisnil in Treating Women With Uterine Fibroids Phase 3
Completed NCT00160381 - A Study to Evaluate the Safety and Effectiveness of Asoprisnil in the Treatment of Uterine Fibroids Phase 3
Recruiting NCT04214457 - Development of a Predictive Model for Early Differential Diagnosis of Uterine Leiomyomas and Leiomyosarcomas
Completed NCT00044876 - Treatment of Uterine Fibroids With CDB-2914, an Experimental Selective Progesterone Receptor Antagonist Phase 2
Completed NCT02889848 - Safety and Tolerability of Collagenase Clostridium Histolyticum (EN3835) to Treat Uterine Leiomyoma (Fibroids) Phase 1
Recruiting NCT04145518 - Mechanistic Characterization of Uterine Pain Phase 4
Completed NCT01816815 - Study in Healthy Tubal Ligated Women to Evaluate Pharmacodynamics, Safety and Pharmacokinetics of BAY1002670 Phase 1
Completed NCT00891657 - Post Market Study for an Adhesion Barrier Following Laparoscopic Myomectomy N/A
Completed NCT00156156 - Study of Asoprisnil in the Treatment of Uterine Fibroids. Phase 3
Recruiting NCT05538689 - Surgical Myomectomy Followed by Oral Myfembree Versus Standard of Care Trial (SOUL) Phase 4
Active, not recruiting NCT03323905 - Single Arm Study Using the Symphony -- MRI Guided Focused Ultrasound System for the Treatment of Leiomyomas N/A
Terminated NCT03342859 - Mode of Action Study of Vilaprisan and Ulipristal Acetate in Patients With Uterine Fibroids for Whom Surgery is Planned Phase 1
Recruiting NCT06135870 - Role of Senescent Cells in Uterine Fibroid Pathogenesis (SOUL Study)
Completed NCT02777203 - Power Morcellation Systems for Laparoscopic Hysterectomy and Myomectomy N/A
Completed NCT02189083 - Study of Tumor-shrinking Decoction (TSD) to Treat Symptomatic Uterine Fibroids Phase 3
Completed NCT01123603 - Lower Urinary Tract Infection (UTI) Evaluation in Women With Uterine Leiomyomata N/A